Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
NCT ID: NCT03188900
Last Updated: 2021-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
236 participants
OBSERVATIONAL
2017-06-12
2019-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Therapeutic Strategy Against Preeclampsia
NCT06464159
Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia
NCT02286284
sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia
NCT05228002
Preeclampsia Ratio (sFlt-1/PlGF)
NCT03289611
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
NCT03815110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP
* Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP
* Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP
* Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP
* Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
preeclampsia
pregnancy with preeclampsia
A collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
control
pregnancy without preeclampsia
A collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton pregnancies between 20 and 41 weeks of gestation
* Preeclampsia
* Normal pregnancy
Exclusion Criteria
* Infectious disease: HIV, HBV or HCV
* Multiple pregnancies
* Opposition of the patient
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
INSERM UMR-S 1139
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edouard Lecarpentier, MD, PhD
Role: STUDY_DIRECTOR
Centre Hospitalier intercommunal de Créteil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Cochin
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003 Nov;88(11):5555-63. doi: 10.1210/jc.2003-030528.
Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol. 2016 Mar;27(3):903-13. doi: 10.1681/ASN.2015020157. Epub 2015 Sep 24.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. doi: 10.1056/NEJMoa031884. Epub 2004 Feb 5.
Trapiella-Alfonso L, Alexandre L, Fraichard C, Pons K, Dumas S, Huart L, Gaucher JF, Hebert-Schuster M, Guibourdenche J, Fournier T, Vidal M, Broutin I, Lecomte-Raclet L, Malaquin L, Descroix S, Tsatsaris V, Gagey-Eilstein N, Lecarpentier E. VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia. Hypertension. 2019 Jul;74(1):145-153. doi: 10.1161/HYPERTENSIONAHA.118.12380. Epub 2019 May 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SC3455
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.